RecruitingPhase 3NCT04766177
Role of Bumetanide in Treatment of Autism
Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children
Sponsor
Sherief Abd-Elsalam
Enrollment
80 participants
Start Date
Jan 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
Role of bumetanide in Autism
Eligibility
Min Age: 3 YearsMax Age: 12 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Bumetanide and a drug called Placebo for people with autism. The study is currently recruiting participants at 1 location. People eligible for this study include aged 3 Years to 12 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBumetanide
bumetanide 0.5 mg twice daily
DRUGPlacebo
placebo tablets twice daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04766177
Related Trials
Differences in Rest, Emotion, and Arousal Modulation in Youth
NCT074769371 location
Improving Caregiver Engagement in Early Interventions
NCT075003631 location
Parent-Mediated Social Cognition Intervention for Young Children With Autism Spectrum Disorder
NCT077082461 location
Family-Centered Implementation of Parent Training for Autistic Toddlers in Early Intervention
NCT074715941 location
A Toolkit to Improve Mental Health Treatment for Autistic Individuals
NCT075395192 locations